Eli Lilly unveiled TuneLab, an AI platform granting select small biotech firms access to advanced drug discovery models developed from decades of Lilly's research data. The initiative aims to accelerate early-stage drug development by sharing predictive models for small molecule properties and antibody assessment at no cost, in exchange for training data contributions to improve the platform. Employing federated learning, TuneLab protects proprietary data while fostering collaboration. This effort expands Lilly’s Catalyze360 program, aiming to democratize AI capabilities across the biotech ecosystem.